Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00230568 · ClinicalTrials.gov registry record · Phase 4
EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)
A Phase 4 study, sponsored by Eisai.
- Completed
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
NCT00230568 is a Phase 4 study that has completed, run by Eisai. The registered enrollment target is 100 participants.
The verdict
NCT00230568, a Phase 4 study, has completed, sponsored by Eisai.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
Study Summary
12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.
Interventions
- DRUG Aricept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2005-12 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00230568
The ClinicalTrials.gov registry entry for NCT00230568 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eisai, which has 287 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aricept is the first listed.
NCT00230568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00230568 about?
NCT00230568 is a clinical study titled "EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)". 12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.
What is the current status of trial NCT00230568?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2005-12. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00230568?
The interventions under investigation include: Aricept (DRUG).
Who is sponsoring clinical trial NCT00230568?
This trial is sponsored by Eisai, which has 287 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.